PT 141 Bremelanotide: Melanocortin Receptor Research Overview

PT-141 (Bremelanotide) at a Glance

PT-141, also known by its generic name bremelanotide, is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH). It was developed from Melanotan II, another melanocortin receptor agonist originally investigated in pigmentation research. In laboratory settings, bremelanotide is studied for its binding and activation of melanocortin receptor subtypes — chiefly MC3R and MC4R — and serves as a reference compound in melanocortin receptor pharmacology.

This overview focuses on the compound's receptor pharmacology, structural chemistry, and the published research literature. It is provided for educational and research purposes only; the peptide is supplied as a research-use material and is not intended for human use.

The Melanocortin Receptor System

Melanocortin receptors are a family of five G-protein-coupled receptors (MC1R–MC5R) activated by the endogenous melanocortin peptides derived from proopiomelanocortin (POMC). The two subtypes most relevant to bremelanotide research are:

• MC3R: Expressed in the central nervous system and periphery; studied for roles in energy homeostasis, circadian regulation, and inflammatory signaling
• MC4R: Expressed predominantly in the brain; a well-characterized regulator of energy balance, thermogenesis, and feeding behavior, and a major locus of melanocortin pharmacology

Both receptors couple to the stimulatory G-protein (Gs) pathway, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). Because the melanocortin system integrates signals relevant to energy homeostasis and behavior, MC3R and MC4R have been central targets in drug-discovery research for decades.

Structure and Analog Design

Bremelanotide is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Its design derives directly from Melanotan II, a cyclic α-MSH analog with a C-terminal carboxamide. In bremelanotide, that C-terminal amide is replaced by a free carboxylic acid — a single structural change that alters the compound's receptor activity and selectivity profile across melanocortin subtypes.

The cyclic lactam bridge constrains the peptide into a defined conformation, which is important for melanocortin receptor recognition. Structure–activity relationship studies in the melanocortin field use this scaffold to probe how ring size, amino acid substitutions, and C-terminal modification shift potency and efficacy at MC3R and MC4R relative to MC1R.

Receptor Pharmacology

Research characterizing bremelanotide focuses on its functional profile at melanocortin receptor subtypes:

• Receptor selectivity: Binding and functional assays evaluate potency and efficacy at MC3R and MC4R versus MC1R (the receptor most associated with melanogenesis)
• Agonist activity: cAMP-accumulation assays measure whether the compound acts as a full or partial agonist at each subtype
• Central nervous system signaling: Studies in hypothalamic and limbic circuits examine how MC3R/MC4R activation translates into downstream neuroendocrine and behavioral effects in animal models
• Off-target assessment: Selectivity panels characterize activity at related GPCRs to define the compound's pharmacological window

This pharmacology is mechanism-focused: the compound is studied as a melanocortin receptor agonist, and reported effects in experimental models are attributed to MC3R/MC4R signaling rather than to peripheral vascular mechanisms.

Published Research and Clinical Studies

The published literature on bremelanotide spans preclinical receptor and behavioral studies and controlled clinical trials. Key areas include:

Preclinical CNS research: Studies in animal models examine how melanocortin receptor activation influences neuroendocrine pathways, including the brain circuits associated with sexual behavior. Pfaus and colleagues reviewed the preclinical CNS profile of bremelanotide, describing melanocortin-mediated signaling in female sexual function models.

Clinical research: Randomized, placebo-controlled trials have evaluated bremelanotide in premenopausal women with hypoactive sexual desire disorder (HSDD). These studies measured changes in self-reported desire and distress using validated instruments such as the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). Reporting of trial endpoints here is limited to describing how the research was conducted; study protocols are not use instructions.

• Clayton and colleagues conducted a randomized, placebo-controlled dose-finding trial in premenopausal women, characterizing the relationship between dose and the desire/distress endpoints
• Kingsberg and colleagues reported two Phase 3 randomized trials using the FSFI and FSDS-DAO instruments to quantify changes in desire and distress

These trials are summarized here as research data. The compounds discussed on this page are laboratory research materials, not approved pharmaceuticals, and nothing here constitutes medical advice or use guidance.

Research Applications

In the laboratory, bremelanotide is used as a pharmacological tool to study the melanocortin system:

• Receptor binding and selectivity profiling across MC1R–MC5R
• cAMP-accumulation functional assays to quantify agonist efficacy
• Structure–activity relationship studies comparing cyclic α-MSH analogs
• Preclinical investigation of MC3R/MC4R signaling in energy homeostasis and neuroendocrine circuits